Chief Business & Legal Officer Joseph Vittiglio resigns; COO Marc Blaustein gets retention bonus and expanded role

Finch Therapeutics Group, Inc.

Joseph Vittiglio resigns as Chief Business and Legal Officer & Secretary, effective Dec 31, 2022.
COO Marc Blaustein assumes business development and investor relations responsibilities after Vittiglio's departure.
Blaustein receives a service-based cash bonus of $83,000, payable in two equal installments (Dec 2022, June 2023).
Blaustein eligible for performance-based cash bonuses up to $332,000 tied to critical corporate objectives set by Compensation Committee.
Service-based bonus repayment required if Blaustein leaves voluntarily (non-Good Reason) or is terminated for Cause before May 31, 2023 (first installment) or Dec 31, 2023 (second).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Marc Blaustein

Chief Operating Officer

FNCHQ · Finch Therapeutics Group, Inc.

Filed: December 12, 2022, 6:59 PM ET

Additionally, on December 7, 2022, the Company entered into a Retention Bonus Agreement with Marc Blaustein, the Company’s Chief Operating Officer, who will also take over business development and investor relations responsibilities following Mr. Vittiglio’s resignation.

Departed

Joseph Vittiglio

Chief Business and Legal Officer and Secretary

FNCHQ · Finch Therapeutics Group, Inc.

Effective: 2022-12-31
Filed: December 12, 2022, 6:59 PM ET

On December 7, 2022, Joseph Vittiglio informed Finch Therapeutics Group, Inc. (the “Company”) of his resignation as the Company’s Chief Business and Legal Officer and Secretary, effective as of December 31, 2022, in order to pursue other professional opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Marc Blaustein changed role as Chief Operating Officer at Finch Therapeutics Group, Inc..

Action: assumed additional responsibilities
Role: Chief Operating Officer

Exact text from the filing

Additionally, on December 7, 2022, the Company entered into a Retention Bonus Agreement with Marc Blaustein, the Company’s Chief Operating Officer, who will also take over business development and investor relations responsibilities following Mr. Vittiglio’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Vittiglio resigned as Chief Business and Legal Officer and Secretary at Finch Therapeutics Group, Inc..

Action: resigned
Role: Chief Business and Legal Officer and Secretary

Exact text from the filing

On December 7, 2022, Joseph Vittiglio informed Finch Therapeutics Group, Inc. (the “Company”) of his resignation as the Company’s Chief Business and Legal Officer and Secretary, effective as of December 31, 2022, in order to pursue other professional opportunities.

View on SEC.gov

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026337

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.